Will Teladoc stock manage to erase recent losses?

6:02 pm 25 April 2022

Teladoc (TDOC.US) has been providing services in the field of remote medicine since 2009. In 2021, the company employed nearly 4,500 doctors on the platform, while the total number of visits amounted to 15.3 million and increased by 38% compared to 2020, which turned out to be a real catalyst for the company's operations. During the pandemic, Teladoc recorded an impressive 86% year-on-year increase in revenues, which contributed to its growing position among companies in the medical industry. However, in the following months company's stock has dropped by more than 80% compared to the price peaks in autumn 2021:

  • Teladoc remains the largest company in the world when it comes to the virtual medicine sector. According to analysts' estimates, the telemedicine market may be worth nearly USD 640 billion by 2028, which gives a nearly 31% annual growth rate;
  • In a report published in February, Teladoc expects an increase in the number of visits by approximately 4.3 million in the current quarter. If the positive forecasts prove correct, and the company is able to maintain such dynamics until the end of 2022, the number of visits may even break the record-breaking 2021, during which patients massively registered visits remotely due to the COVID pandemic and lockdowns;
  • Estimated revenues for the quarter are to amount to approximately USD 565 million, Teladoc also expects a decrease in net loss per share to USD 0.50 compared to 1.38 in Q1 2021;
  • Earnings per share for the previous quarter beat analysts' expectations by almost 88%;
  • One of the company's largest shareholders is the ArkInvest fund, run by Cathie Wood, known for its high-profile success in recent years, when the fund's portfolio achieved record results, and Cathie Wood was recognized as one of the most effective portfolio fund managers from Wall Street;
  • The valuation of ETFs operated by ArkInveest has suffered significantly from a shift in the Fed's monetary policy and investors' retreat from risky assets. ArkInvest continues to operate, and Wood upholds long-term forecasts for all companies in the fund's portfolio and announces an 'burst of innovation' which is contradictory to most analysts which are pointing to several risk factors;
  • In February 2022, Teladoc signed an agreement with Amazon, which may bring the company a lot of additional clients in the coming years, but this was not met with a euphoric reaction from the market;
  • Consumer demand confirms that the trend of remote medicine development may go beyond the pandemic and the demand for this kind of services may continue to rise. A Forbes study shows that approximately 63% of respondents would be willing to use remote medicine again;
  • The company has historically struggled to obtain all the necessary licenses to operate in all US states, including Texas, but these obstacles have been overcome and is now operating smoothly;
  • The trend among medical and pharmaceutical companies led to a market euphoria during the pandemic, which ended with a panic sell-off after the pandemic ceased to be the primary factor influencing the market and investor behavior. 
  • The main threat to Teladoc expansion is a declining number of new clients and shrinking cash flow, which may not cover the huge expenses incurred by the company due to the scaling of its operations;
  • In periods of economic uncertainty, investors usually move away from unprofitable assets only to buy them when the market starts to recover with a simultaneous change in the economic background (e.g. monetary tightening / loosening).
  • Until the firm proves profitable, the stock will likely be very volatile due to investor uncertainty and market sentiment.
  • On April 27, Teladoc will publish its financial results for the first quarter of 2022.

Teladoc (TDOC.US), interval W1. The share price is approaching the 2018 lows, although the company has expanded significantly since then. On the other hand, the sellers' pressure is not waning so far.  The nearest resistance is located around the psychological $ 100 level. Source: xStation5

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.

Share:
Back

Join over 1 600 000 XTB Group Clients from around the world.